Clinical Trial

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the effect of carbamazepine on the blood levels of mirdametinib and how long it takes the body to eliminate mirdametinib when both drugs are administered orally in healthy participants. The study may last up to approximately 64 days for each participant.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Completed 2026-04-02
minor Completion moved earlier: 2026-10 -> 2026-02-27 2026-04-02
Trial Details
NCT Number NCT07279233
Lead Sponsor SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Conditions Healthy, Volunteer
Enrollment 36 participants
Start Date 2025-12-15
Primary Completion 2026-02-27 (estimated)
Study Completion 2026-02-27 (estimated)
Updated on ClinicalTrials.gov 2026-05-08